Tau protein kinases: involvement in Alzheimer's disease

L Martin, X Latypova, CM Wilson, A Magnaudeix… - Ageing research …, 2013 - Elsevier
Tau phosphorylation is regulated by a balance between tau kinase and phosphatase
activities. Disruption of this equilibrium was suggested to be at the origin of abnormal tau …

A de novo convergence of autism genetics and molecular neuroscience

N Krumm, BJ O'Roak, J Shendure, EE Eichler - Trends in neurosciences, 2014 - cell.com
Autism spectrum disorder (ASD) and intellectual disability (ID) are neurodevelopmental
disorders with large genetic components, but identification of pathogenic genes has …

[HTML][HTML] A transcription factor atlas of directed differentiation

J Joung, S Ma, T Tay, KR Geiger-Schuller… - Cell, 2023 - cell.com
Transcription factors (TFs) regulate gene programs, thereby controlling diverse cellular
processes and cell states. To comprehensively understand TFs and the programs they …

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

S Lin, BT Staahl, RK Alla, JA Doudna - elife, 2014 - elifesciences.org
The CRISPR/Cas9 system is a robust genome editing technology that works in human cells,
animals and plants based on the RNA-programmed DNA cleaving activity of the Cas9 …

Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders

BJ O'Roak, L Vives, W Fu, JD Egertson, IB Stanaway… - Science, 2012 - science.org
Exome sequencing studies of autism spectrum disorders (ASDs) have identified many de
novo mutations but few recurrently disrupted genes. We therefore developed a modified …

De novo gene disruptions in children on the autistic spectrum

I Iossifov, M Ronemus, D Levy, Z Wang, I Hakker… - Neuron, 2012 - cell.com
Exome sequencing of 343 families, each with a single child on the autism spectrum and at
least one unaffected sibling, reveal de novo small indels and point substitutions, which come …

A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication

P Wang, JC Alvarez-Perez, DP Felsenfeld, H Liu… - Nature medicine, 2015 - nature.com
Abstract Types 1 and 2 diabetes affect some 380 million people worldwide. Both ultimately
result from a deficiency of functional pancreatic insulin-producing beta cells. Beta cells …

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in D own syndrome mouse models and in humans

R De la Torre, S De Sola, M Pons… - Molecular nutrition & …, 2014 - Wiley Online Library
Scope Trisomy for human chromosome 21 results in D own syndrome (DS), which is among
the most complex genetic perturbations leading to intellectual disability. Accumulating data …

The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation

LP Van Der Heide, MFM Hoekman… - Biochemical …, 2004 - portlandpress.com
FoxO (forkhead box O; forkhead members of the O class) are transcription factors that
function under the control of insulin/insulin-like signalling. FoxO factors have been …

NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21

JR Arron, MM Winslow, A Polleri, CP Chang, H Wu… - Nature, 2006 - nature.com
Trisomy 21 results in Down's syndrome, but little is known about how a 1.5-fold increase in
gene dosage produces the pleiotropic phenotypes of Down's syndrome. Here we report that …